AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

SXTP · NASDAQ · Biotechnology

60 Degrees Pharmaceuticals (SXTP)

Develops and markets tafenoquine medicines for malaria prevention and vector-borne diseases.

$0.9600

Pre-market−0.01 (−1.02%)

At close$0.9699(−4.91%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions8 holders · as of Mar 31, 2026	5.53%	194.3K shares
Insiders4 holders · as of Jun 15, 2026	0.95%	33.3K shares
Strategic holders2 holders · as of Jul 29, 2026	21.00%	738.6K shares
Otherremainder	72.52%	2.55M shares

3.52M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Two share counts disagree (3.52M in the company's Sep 3, 2026 report, 806.6K elsewhere); stakes use the report.

A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Knight Therapeutics Inc.Strategic10 percent owner	18.73%	658,629	13Gfiled Jul 29, 2026 ↗
Lind Global Fund III LPInstitution	5.45%	191,571	13Gfiled Aug 5, 2026 ↗
Kathmere Capital Management, LLCInstitution	4.11%	144,683	13Fas of Mar 31, 2026
Orca Capital AGStrategic	2.27%	80,000	13Gfiled Jul 17, 2025 ↗
UBS Group AGInstitution	0.89%	31,410	13Fas of Mar 31, 2026
Geoffrey S. DowInsiderdirector, officer: President and CEO	0.77%	26,911	Form 4filed Jun 15, 2026 ↗
Geode Capital Management, LLCInstitution	0.46%	16,295	13Fas of Mar 31, 2026
Cheryl XuInsiderdirector	0.11%	3,954	Form 4filed Jun 5, 2025 ↗
Barclays PLCInstitution	0.05%	1,856	13Fas of Mar 31, 2026
Tyrone MillerInsiderofficer: CFO	0.04%	1,319	Form 4filed Jan 21, 2025 ↗
Kristen LandonInsiderofficer: Chief Operating Officer	0.03%	1,135	Form 4filed Aug 14, 2025 ↗
Newedge Advisors, LLCInstitution	0.00%	50	13Fas of Mar 31, 2026
Advisor Group Holdings, Inc.Institution	0.00%	25	13Fas of Mar 31, 2026
Twin Peaks Wealth Advisors, LLCInstitution	0.00%	8	13Fas of Mar 31, 2026
Citigroup IncInstitution	0.00%	1	13Fas of Mar 31, 2026
Armistice Capital, LLCStrategic	—9.99% of class, as filed	—	13Gfiled Feb 14, 2025 ↗
CVI Investments, Inc.Strategic	—9.90% of class, as filed	—	13Gfiled Nov 7, 2025 ↗
Mitchell P. KopinInsider	—9.99% of class, as filed	—	13Gfiled Nov 7, 2025 ↗
Kentucky Technology Inc.¹Strategic10 percent owner	0.06%	2,188	Form 4filed Jul 11, 2023 ↗
Florida State University Research Foundation Inc.¹Strategic10 percent owner	0.05%	1,688	Form 4filed Jul 11, 2023 ↗
Charles W. Allen²Insiderdirector	0.00%	58	Form 4filed May 21, 2024 ↗
Paul Field²Insiderdirector	0.00%	58	Form 4filed May 21, 2024 ↗
Stephen Toovey²Insiderdirector	0.00%	58	Form 4filed May 21, 2024 ↗

Last filed Jul 11, 2023; leaving the company requires no filing. Not in the bar.
Last filed May 21, 2024; leaving the company requires no filing. Not in the bar.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

8 holders · 194.3K shares

Holder	Shares	% outstanding	Filed
Kathmere Capital Management, LLC	144.7K	4.11%	Apr 28, 2026
UBS Group AG	31.4K	0.89%	May 5, 2026
Geode Capital Management, LLC	16.3K	0.46%	May 15, 2026
Barclays PLC	1.9K	0.05%	May 15, 2026
Newedge Advisors, LLC	50	0.00%	Jun 3, 2026
Advisor Group Holdings, Inc.	25	0.00%	May 15, 2026
Twin Peaks Wealth Advisors, LLC	8	0.00%	May 8, 2026
Citigroup Inc	1	0.00%	May 11, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Knight Therapeutics Inc.	19.85%	658.6K	13G	Jul 29, 2026 ↗
Mitchell P. Kopin	9.99%		13G	Nov 7, 2025 ↗
Armistice Capital, LLC	9.99%		13G	Feb 14, 2025 ↗
CVI Investments, Inc.	9.90%		13G	Nov 7, 2025 ↗
Orca Capital AG	9.90%		13G	Jul 17, 2025 ↗
Lind Global Fund III LP	5.45%	191.6K	13G	Aug 5, 2026 ↗

Insider tradesForm 4

Latest trades

Date	Insider	Type	Shares	Avg price	Owned after
Jun 12, 2026	Geoffrey S. Dowdirector, officer: President and CEO	Purchase	7,350	$1.38	24,131
Dec 15, 2025	Geoffrey S. Dowdirector, officer: President and CEO	Purchase	9,670	$0.8024	59,618
Dec 10, 2025	Geoffrey S. Dowdirector, officer: President and CEO	Purchase	9,350	$0.9504	46,335
Dec 11, 2025	Geoffrey S. Dowdirector, officer: President and CEO	Purchase	3,613	$0.9184	49,948

CongressHouse and Senate disclosures

Not reported.